Table 1 Separation of T2D patients participating in CVOTs according to the presence (secondary prevention) or absence (primary prevention) of established CVD
Trial | Drug | Primary prevention | Secondary prevention |
|---|---|---|---|
EMPA-REG | Empagliflozin | 56 (0.8%) | 6964 (99.2%) |
CANVAS | Canagliflozin | 2819 (27.8%) | 7323 (72.2%) |
DECLARE | Dapagliflozin | 10 193 (59.4%) | 6967 (40.6%) |
VERTIS-CV | Ertugliflozin | 82 (1%) | 8155 (99%) |
SCORED | Sotagliflozin | 5440 (51.4%) | 5144 (48.6%) |
Total | 18 590 (35.0%) | 34 553 (65.0%) |